Abstract Library

#2167 Evaluation of Streptozocin-Based Chemotherapeutic Regimens for Advanced Pancreatic Neuroendocrine Tumors: A Multi-Center Clinical Study in Japan

Introduction: Streptozocin (STZ) has been used as a key drug against advanced pancreatic neuroendocrine tumors (pNETs). The standard in many countries is a daily STZ regimen combined with 5-fluorouracil administered once daily for 5 days every 6 weeks. However, in Japan, STZ was only covered by insurance beginning in 2015, and STZ is often used as monotherapy, as either a daily or a weekly regimen. There are few reports on STZ monotherapy for pNETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Sakamoto Y, Hijioka S, Shibuya H, Ito T, Imamura M,

Keywords: Streptozocin, pNETs,

#1657 Establishment of Japan NeuroEndocrine Tumor Society and Its Registration System

Introduction: In 2012, many nation-wide gastroenterologists, endocrinologists, surgeons, radiologists and pathologists have established Japan NeuroEndocrine Tumor Society (JNETS) in Japan. JNETS is now composed of 304 institutes.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Masui T

Authors: Masui T, Imamura M, Ito T, Unno M, Okusaka T,

Keywords: registry system, Japan,,

#823 Association Between Tumor Expression of VEGFA, VEGFR1 (FLT1), VEGFR2 (KDR), and Clinical Outcomes in Neuroendocrine Tumors

Introduction: Clinical studies have suggested efficacy of VEGF pathway inhibitors in the treatment of advanced neuroendocrine tumors (NETs).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Qian Z

Authors: Qian Z, Ter-Minassian M, Chan J, Imamura Y, Hooshmand S,

Keywords: VEGF, bevacizumab, NET survival,